How GLP-1 agonist receptors contribute to higher risk populations?

Abstract

The increase in the prevalence of type 2 diabetes mellitus type 2 (T2DM) is related to the aging of the population, among other factors. Likewise, these patients have an increased risk of progression to chronic kidney disease and an increased cardiovascular risk (CV). The treatment of T2DM in these subgroups is complex; in this context, drug therapies should offer proven efficacy and safety in these populations. In response to these needs, glucagon-like peptide 1 receptor agonists are positioned as one of the treatments of choice.